Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

Executive Summary

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.

You may also be interested in...



The Good, The Bad And The Ugly Of COVID-19 Vaccine Manufacturing Technology Platforms

Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.

Stability Genius: How CMC Section Of COVID-19 Vaccine Guidance Speeds EUAs Safely

By focusing on short-term stability, US FDA paves way for quicker emergency use authorization without compromising on quality.

From COVID Cliff To GLP-1 Ramp: Novo Takes Catalent Plants For Next Public Health Crisis

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel